Drug packages to lose weight WOGOVY, Ozempic and Mounjaro.
Image Alliance | Getty images
A version of this article appeared for the first time in the Healthy Bulletin returns from CNBC, which brings the latest medical care news directly to its entrance tray. Subscribe here To receive future editions.
Most people leave a very popular class of weight loss and diabetes called GLP-1 within a year after starting them, they have demonstrated several studies.
But new research has more details about who is more likely to remain in expensive medications, which cost approximately $ 1,000 per month before insurance and other reimbursements. Many insurance plans cover LPG-1 for type 2 diabetes, but not for obesity.
About 65% of patients without type 2 diabetes suspended LPG-1 in less than a year, according to a study published Friday at Jama Network Open, a medical magazine. Those with type 2 diabetes were less likely to give up medications within a year, in approximately 46%.
These rates were around 84% compared to 64%, respectively, to stop the LPG-1 in two years.
The study said that side effects and adverse cost were the most common reasons documented in clinical notes for patients stopping medications.
People with less side effects were also less likely to stop treatment with LPG-1, according to the study, which is consistent with previous research. LPG-1 are linked to gastrointestinal side effects moderate to severe, such as nausea and vomiting.
The highest income was also progressively associated with a lower interruption rate between those with diabetes in particular, according to the study. The researchers compared different income interviews, ranging from patients with income below $ 30,000 to people with income of more than $ 80,000.
But the study also found that the results are important for patients with and without diabetes, since those who lost more weight were more likely to remain in medicines. People who recovered the weight after arresting LPG-1 also were more likely to give medications a second attempt.
“The associations between weight loss and interruption and between weight recovery and reinitiation suggest that weight control is an important factor regardless of the state of type 2 diabetes,” wrote the authors of the study.
The investigation is based on a review of electronic health records in more than 125,000 adults who began to take GLP-1 medicines (liraglutida, semaglutida or tirzepatida) between January 2018 and December 2023. The semaglutide is the active ingredient in Novo NordiskThe medication to lose weight of the counterpart of diabetes and diabetes Ozempic, and the tirzepatide is the active ingredient in LillyInjection of obesity of obesity and drugs of Mounjaro diabetes.
Do not hesitate to send any advice, suggestion, stories ideas and data to Annika in [email protected].
The latest in medical care technology: NOOM reduces staff to focus on rapid GP-1 products
The NOOM metabolic health startup is saying part of its staff, since it focuses its workforce in “the most critical areas of the business”, including weight loss and diabetes medications, the company confirmed to CNBC on Monday.
NOOM offers a range of behavioral and medically assisted weight loss programs. NOOM MED members can access several of the popular drug class to lose weight known as LPG-1, including Ozempic and Novo Nordisk Wegovy. In September, Noom announced that it would also offer compound semaglutida, the same active ingredient in Novo Nordisk brand medications, through a new program called LPG-1 (RX).
The company said recent layoffs were the result of a change in income mixture to its rapid LPG-1 offers, such as LPG-1 (RX). Noom is investing strongly in that business, he added.
“In an effort to build a more efficient business focused on the needs of our clients, we made the difficult decision to reduce a part of our workforce,” said a NOOM spokesman for CNBC in a statement. “With these changes, the company will be better positioned to offer world -class -class technology, technology and coaching for more people seeking healthier lives.”
NOOM did not confirm the number of employees affected by dismissals.
Endpoints News first reported the cuts.
LPG-1 medicines are usually much cheaper than their brand counterparts, since Wogovy and Ozempic cost approximately $ 1,000 per month before insurance. NOOM GLP-1 (RX) costs participants $ 149 for their first month, and $ 279 for the following months as the dose of their medications increases.
Composite medications can be produced as alternatives tailored to brand medications, as well as when there is a shortage of brand treatments. In addition to Noom, several digital health companies such as HIMS & Hers, Ro and Sesame have been offering compound GLP-1 medications as consumers sail for the demand for increase and irregular insurance coverage.
Some analysts estimate that obesity medications could become an industry of $ 100 billion for the end of the decade.
Do not hesitate to send any advice, suggestion, stories ideas and data to Ashley at [email protected].
